Your browser doesn't support javascript.
loading
Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial.
Berk, Michael; Daglas, Rothanthi; Dandash, Orwa; Yücel, Murat; Henry, Lisa; Hallam, Karen; Macneil, Craig; Hasty, Melissa; Pantelis, Christos; Murphy, Brendan P; Kader, Linda; Damodaran, Saji; Wong, Michael T H; Conus, Philippe; Ratheesh, Aswin; McGorry, Patrick D; Cotton, Sue M.
Afiliação
  • Berk M; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Daglas R; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Dandash O; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Yücel M; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Henry L; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Hallam K; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Macneil C; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Hasty M; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Pantelis C; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Murphy BP; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Kader L; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Damodaran S; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Wong MTH; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Conus P; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Ratheesh A; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • McGorry PD; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
  • Cotton SM; Michael Berk, MBBCh, PhD, Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health and the Geelong Clinic; Orygen, The National Centre of Excellence in Youth Mental Health, the Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Univers
Br J Psychiatry ; 210(6): 413-421, 2017 06.
Article em En | MEDLINE | ID: mdl-28254958
ABSTRACT
BackgroundLithium and quetiapine are considered standard maintenance agents for bipolar disorder yet it is unclear how their efficacy compares with each other.AimsTo investigate the differential effect of lithium and quetiapine on symptoms of depression, mania, general functioning, global illness severity and quality of life in patients with recently stabilised first-episode mania.MethodMaintenance trial of patients with first-episode mania stabilised on a combination of lithium and quetiapine, subsequently randomised to lithium or quetiapine monotherapy (up to 800 mg/day) and followed up for 1 year. (Trial registration Australian and New Zealand Clinical Trials Registry - ACTRN12607000639426.)ResultsIn total, 61 individuals were randomised. Within mixed-model repeated measures analyses, significant omnibus treatment × visit interactions were observed for measures of overall psychopathology, psychotic symptoms and functioning. Planned and post hoc comparisons further demonstrated the superiority of lithium treatment over quetiapine.ConclusionsIn people with first-episode mania treated with a combination of lithium and quetiapine, continuation treatment with lithium rather than quetiapine is superior in terms of mean levels of symptoms during a 1-year evolution.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Bipolar / Compostos de Lítio / Fumarato de Quetiapina Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Br J Psychiatry Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Bipolar / Compostos de Lítio / Fumarato de Quetiapina Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Br J Psychiatry Ano de publicação: 2017 Tipo de documento: Article